Rolofylline: Additional Phase III data

Additional data from the double-blind, international Phase III PROTECT trial in 2,033 patients showed that 30 mg/day IV rolofylline for up to 3 days led to persistent renal impairment in 15% of patients vs. 13.7% for placebo (p=0.44). Furthermore, there was no significant difference between treatment groups in the proportion of patients in which death or readmission for cardiovascular or renal causes had occurred at day 60 (30.7% vs. 31.9%, p=0.86). ...